Category: Regulatory Affairs
Compiling IND/NDA/BLA/MAA dossiers is document-heavy and time-pressured, with authoring effort gating filing timelines.
Regulatory submissions are document-intensive and deadline-driven, and authoring and compilation effort frequently sits on the critical path to filing. AI-assisted authoring and biosimulation tools help draft and assemble submission components, reuse prior content, and support modeling that strengthens the dossier — reducing manual effort and timeline risk.
Submission-authoring AI works on the documents that make up a regulatory dossier — clinical and nonclinical summaries, overviews, and the supporting narratives that consume most of a writing team's time. Generative tools produce first drafts from structured source data and prior approved content, working inside controlled templates so output follows the expected structure and style. Related document-intelligence capabilities locate relevant content across earlier submissions so authors start from what the organization has already written and approved rather than a blank page. The realistic goal is a better first draft, faster — not an authorless submission. Medical writers and regulatory professionals review, correct, and approve everything that goes into a dossier, and accountability for the filing stays with the sponsor. The value is in removing transcription, formatting, and searching from expert workloads so their time goes to scientific content and strategy.
Draft quality on your own document types is the deciding factor, so ask a vendor to work from a representative source package — your data tables, your templates, your style guide — rather than a polished demo. Probe traceability: a reviewer should be able to follow any generated statement back to the source data or prior document it came from, because an unsupported sentence in a regulatory document is a serious liability. Ask how the tool behaves when source data is missing or ambiguous — it should flag the gap, not fill it. Because the output enters regulated workflows, examine audit trails, versioning, and how the system fits controlled authoring and review processes, including 21 CFR Part 11 expectations where they apply. Also weigh integration with your existing document management and regulatory information systems, and how enforced human review is before anything advances in the workflow.
A common entry point is piloting one document type — a module summary or a defined narrative type — on a program with a real deadline several months out. The team drafts with the tool and measures revision effort against its normal baseline: how much of the generated draft survives review, where it errs, and whether authors trust it enough to keep using it. That produces internal evidence on quality and time saved before the tool is relied on for a filing-critical path.
It produces first drafts of submission documents from structured source data and previously approved content, working within controlled templates, and it retrieves relevant prior content so authors don't start from a blank page. Medical writers and regulatory professionals review and approve everything — the tool accelerates drafting, it does not replace authorship or accountability.
No. Every statement in a regulatory dossier is the sponsor's responsibility, and agencies expect qualified professionals to stand behind the content. Credible tools are built around enforced human review — the draft is a starting point, and the accountable author decides what is submitted.
Acceptability depends on how the system is controlled, not on the algorithm: validated workflows, audit trails, version control, enforced review steps, and traceability from generated text back to source data. Ask vendors for their validation documentation and how their workflow keeps a qualified person responsible for each document.
Ask them to draft from your real source package and templates, show how generated statements trace back to source data, demonstrate what happens when data is missing, and walk through audit trails and review enforcement. Also probe integration with your document management system and which document types they support well today versus on a roadmap.
The U.S. FDA renewed and expanded its long-standing collaboration licensing Certara's Simcyp physiologically-based pharmacokinetic (PBPK) simulator, with hundreds of agency licenses used to inform regulatory review of drug dosing and interactions.
Vendor: Certara · press release (Certara (GlobeNewswire)) · 2021-12-21 — Partner: U.S. FDA
Yseop announced a strategic investment and a milestone of clinical trials supported by its generative AI for regulatory and medical writing.
Vendor: Yseop · press release (Yseop (GlobeNewswire)) · 2023-12-07